论文部分内容阅读
卵巢癌的发病率在女性生殖器恶性肿瘤中占第三位,但其患者死亡率却居首位[1]。在细胞减灭术的基础上施以以顺铂为主的联合化疗方案已成为卵巢癌的常规治疗方案。据报道:Ⅲ和Ⅳ期的卵巢癌患者采用联合化疗,其完全缓解率可达60%～80%,但在实际临床应用中却并非如此,近30年来卵巢癌患者的5年生存率一直徘徊于30%～50%之间。其主要原因就是卵巢癌对化疗药物产生了耐受性。约75%～80%的卵巢上皮癌开始对化疗有反应,其余则表现为原发耐药,最终所有化疗患者至少80%出现耐药[2]。因此,耐药的产生直接影响化疗效果及生存率。如何尽早发现耐药及克服耐药是急需解决的问题。
The incidence of ovarian cancer is the third highest among female genital malignancies, but its mortality rate ranks first [1]. Cytoreductive surgery based on cisplatin-based combination chemotherapy has become a routine treatment of ovarian cancer. It is reported that: Ⅲ and Ⅳ ovarian cancer patients with combination chemotherapy, the complete remission rate of 60% to 80%, but in actual clinical application is not the case, the last 30 years, ovarian cancer patients 5-year survival rate has been hovering Between 30% ~ 50%. The main reason is that ovarian cancer has become resistant to chemotherapy drugs. About 75% to 80% of ovarian epithelial cancers begin to respond to chemotherapy, while others show primary drug resistance, with at least 80% of patients eventually receiving chemotherapy resistant [2]. Therefore, drug resistance has a direct impact on the efficacy of chemotherapy and survival. How to detect drug resistance and overcome drug resistance is an urgent problem to be solved.